Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ONCTERNAL THERAPEUTICS, INC.

(ONCT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of cancers with critical unmet medical need. The Company’s clinical pipeline includes cirmtuzumab, TK216, ROR1 CAR-T. Cirmtuzumab is a monoclonal antibody that is designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL). TK216 is a small molecule inhibiting the biological activity of E26 transformation-specific (ETS)-family transcription factor oncoproteins. The Company is also developing a ROR1-targeted CAR-T cell therapy candidate utilizing the binding domain of cirmtuzumab as a single-chain variable region fragment (scFv) for the treatment of patients with aggressive hematological malignancies or solid tumors.

Number of employees : 14 people.
Sales per Business
20192020Delta
Novel Oncology Therapies2.43100%3.38100% +39.18%
USD in Million
Sales per region
20192020Delta
United States2.43100%3.38100% +39.18%
USD in Million
Managers
Name Title Age Since
James B. Breitmeyer, Dr. President, Chief Executive Officer & Director 67 2015
Richard Glenn Vincent Chief Financial Officer, Secretary & Treasurer 58 2017
Rajesh Krishnan, Dr. Chief Technology Officer - -
Gunnar F. Kaufmann, Dr. Chief Scientific Officer 45 2019
Salim Yazji, Dr. Chief Medical Officer - 2021
David F. Hale Director 72 1997
Daniel L. Kisner, Dr. Independent Director 74 2019
William R. LaRue Independent Director 69 2017
Xin Nakanishi, Dr. Independent Director 59 2018
Charles P. Theuer, Dr. Independent Director 57 2018
Members of the board
Name Title Age Since
David F. Hale Director 72 1997
James B. Breitmeyer, Dr. President, Chief Executive Officer & Director 67 2015
Daniel L. Kisner, Dr. Independent Director 74 2019
William R. LaRue Independent Director 69 2017
Xin Nakanishi, Dr. Independent Director 59 2018
Charles P. Theuer, Dr. Independent Director 57 2018
Michael G. Carter, Dr. Independent Director 83 2019
Robert James Wills, Dr. Independent Director 67 2019
Rosemary Mazanet Independent Director 65 2021
Jinzhu Chen Director - 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 49,427,220 43,345,359 87.7% 0 0.0% 87.7%
Shareholders
NameEquities%
Shanghai Pharmaceuticals Holding Co., Ltd 3,544,431 7.17%
The Vanguard Group, Inc. 2,074,536 4.20%
Armistice Capital LLC 1,316,163 2.66%
BlackRock Fund Advisors 1,231,428 2.49%
Nantahala Capital Management LLC 1,200,747 2.43%
Joseph R. Hyde 1,176,871 2.38%
SSgA Funds Management, Inc. 807,637 1.63%
Geode Capital Management LLC 762,449 1.54%
683 Capital Management LLC 728,890 1.47%
Hale BioPharma Ventures LLC 713,152 1.44%
Company contact information
Oncternal Therapeutics, Inc.
12230 El Camino Real
Suite 300
San Diego, CA 92130

Phone : +1.858.434.1113
Fax : +858.408.3010
Web : http://www.oncternal.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Oncternal Therapeutics, Inc.